ESPE2015 Poster Category 3 Turner (14 abstracts)
Pediatric Department, First Affiliated Hospital, Sun Yat-Sen University, GuangZhou, China
Objective and hypotheses: To compare the different efficacies between recombinant human GH (rhGH) alone and rhGH combined with low does stanozolol on improving growth of the girls with Turner syndrome (TS).
Method: TS girls were divided into two groups. Group 1 (15 cases) received rhGH therapy, aged (13.09±2.70) years, bone age (11.00±1.01) years, height was (131.46±8.22) cm. Group 2 (22 cases) received low does stanozolol combined with rhGH therapy, aged (13.37±2.09) years, bone age was (11.04±0.86) years, height was (129.21±8.19) cm. Treatment periods were one year. Growth velocity (GV), height S.D. score (HtSDS), ΔHtSDS, the change of bone age over the change of chronologic age (ΔBA/ΔCA) for both groups were measured or calculated.
Results: The GV was (6.33±1.44) cm/a and (8.13±1.87) cm/a for group 1 and 2 respectively, HtSDS change from (−3.44±1.02) to (−3.06±1.09) and (−4.21±1.19) to (−3.43±1.06), and ΔBA/ΔCA was (0.63±0.40) and (0.77±0.56) for group 1 and 2 respectively. The GV and change of HtSDS for group 2 were significantly better than group 1 (P<0.05). The GV was negative correlation with the age.
Conclusion: Comparing to the therapy with rhGH alone, combined therapy with rhGH and low dose stanazolol has advantage on improving GV without accelerating bone maturation among the girls with TS.